Healthcare / Medical Instruments & SuppliesStockholm
$55.50
+0.20 (+0.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $902.0M · quality 60.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.9B
P/E
16.0x
↓EV/EBITDA
6.9x
↓ROE
18.6%
↑Gross Margin
74.7%
↑Debt/Equity
1.46
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.4%
FCF CAGR
+45.5%
FCF margin
13.2%
FCF / Net income
2.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.20B · net income $454.0M · FCF $949.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.20B | $7.20B | $6.52B | $5.98B | $5.35B |
| Net Income | $454.0M | $454.0M | $366.0M | $311.0M | $328.0M |
| EBITDA | $1.60B | $1.60B | $1.48B | $1.35B | $1.18B |
| EPS | 3.14 | 3.14 | 2.48 | 2.08 | 2.19 |
| Gross Margin | 74.7% | 74.7% | 75.6% | 75.8% | 76.1% |
| Operating Margin | 12.0% | 12.0% | 12.6% | 11.6% | 10.3% |
| Net Margin | 6.3% | 6.3% | 5.6% | 5.2% | 6.1% |
| Balance Sheet | |||||
| Debt/Equity | 1.46 | 1.46 | 1.36 | 1.31 | 1.33 |
| Current Ratio | 1.11 | 1.11 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $949.0M | $949.0M | $556.0M | $902.0M | $308.0M |
| Returns | |||||
| ROE | 18.6% | 18.6% | 14.3% | 12.4% | 12.7% |
| Valuation | |||||
| P/E | 16.04 | 16.04 | 17.98 | 21.54 | 18.18 |
| EV/EBITDA | 6.87 | 6.87 | 6.52 | 6.98 | 7.58 |
| P/B | 3.29 | 3.29 | 2.58 | 2.65 | 2.31 |
| Growth & Yield | |||||
| Revenue Growth | 10.4% | 10.4% | 9.0% | 11.9% | — |
| EPS Growth | 26.6% | 26.6% | 19.2% | -5.0% | — |
| Dividend Yield | 3.3% | 3.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
16.2%
EPS terminal req.
$4.92
Spread vs growth
10.4%
5Y implied EPS CAGR
13.7%
EPS terminal req.
$5.96
Spread vs growth
12.9%
10Y implied EPS CAGR
11.8%
EPS terminal req.
$9.60
Spread vs growth
14.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+13.2%
Start / end P/E
20.4x → 17.7x
EPS bridge
2.48 → 3.14
Residual
-3.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.